Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1983 1
1991 1
1992 5
1993 2
1994 4
1995 9
1996 2
1997 5
1998 3
1999 7
2000 10
2001 6
2002 4
2003 7
2004 6
2005 8
2006 6
2007 11
2008 6
2009 17
2010 13
2011 14
2012 17
2013 19
2014 14
2015 12
2016 8
2017 12
2018 14
2019 8
2020 5
2021 4
2022 8
2023 2
2024 2
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean solo g[au] (1 results)?
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Howard FM, Dolezal J, Hieromnimon H, Venters S, Kochanny S, Li A, Borowsky A, Symmans WF, Wolf D, Brown-Swigart L, Sun A, Basu A, Hirst G, Nguyen LC, Asare A, Kanaparthi S, Khramtsova G, Blenman K, Shan NL, Fan C, Tolaney SM, Somlo G, Hudis CA, Sikov W, McCart L, Watson M, Carey L, Stover DG, Veer LV, Esserman LJ, Perou CM, Pusztai L, Olopade OI, Huo D, Nanda R, Pearson AT. Howard FM, et al. Among authors: somlo g. medRxiv [Preprint]. 2025 Aug 27:2025.08.25.25334393. doi: 10.1101/2025.08.25.25334393. medRxiv. 2025. PMID: 40909848 Free PMC article. Preprint.
Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.
Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Banerjee R, et al. Among authors: somlo g. Leukemia. 2025 Apr;39(4):1001-1004. doi: 10.1038/s41375-025-02534-5. Epub 2025 Feb 24. Leukemia. 2025. PMID: 39994463 Free PMC article. No abstract available.
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T. Pasquini MC, et al. Among authors: somlo g. J Clin Oncol. 2024 Aug 10;42(23):2757-2768. doi: 10.1200/JCO.23.00934. Epub 2024 May 3. J Clin Oncol. 2024. PMID: 38701390 Free PMC article. Clinical Trial.
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Ladbury C, Sanchez J, Chowdhury A, Palmer J, Liu A, Stein A, Htut M, Farol L, Cai JL, Somlo G, Rosenzweig M, Wong JC, Sahebi F. Ladbury C, et al. Among authors: somlo g. Am J Clin Oncol. 2024 Jul 1;47(7):325-332. doi: 10.1097/COC.0000000000001095. Epub 2024 Mar 14. Am J Clin Oncol. 2024. PMID: 38483213 Clinical Trial.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: somlo g. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Lavasani SM, et al. Among authors: somlo g. Cancer. 2023 Mar 1;129(5):740-749. doi: 10.1002/cncr.34589. Epub 2022 Dec 14. Cancer. 2023. PMID: 36517940 Free PMC article. Clinical Trial.
248 results